Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab

BACKGROUND: Anti-PD-1 agents were approved for advanced melanoma after the landmark trial Checkmate-037. Anti-PD-1 agents can breach immunologic tolerance. Fulminant diabetes is an immune endocrinopathy that results from a violent immune attack leading to complete destruction of pancreatic beta cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Chokr, Nora, Farooq, Hafsa, Guadalupe, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830024/
https://www.ncbi.nlm.nih.gov/pubmed/29623227
http://dx.doi.org/10.1155/2018/8981375

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830024/
https://www.ncbi.nlm.nih.gov/pubmed/29623227
http://dx.doi.org/10.1155/2018/8981375

Ejemplares similares